RESEARCH ARTICLE

Structural Characterisation of FabG from *Yersinia pestis*, a Key Component of Bacterial Fatty Acid Synthesis

Jeffrey D. Nanson¹, Jade K. Forwood¹,²*

¹ School of Biomedical Sciences, Charles Sturt University, Wagga Wagga, NSW, 2678, Australia, ² Graham Centre for Agricultural Innovation, Charles Sturt University, Wagga Wagga, NSW, 2678, Australia

* jforwood@csu.edu.au

Abstract

Ketoacyl-acyl carrier protein reductases (FabG; EC 1.1.1.100) are ubiquitously expressed enzymes that catalyse the reduction of acyl carrier protein (ACP) linked thioesters within the bacterial type II fatty acid synthesis (FASII) pathway. The products of these enzymes, saturated and unsaturated fatty acids, are essential components of the bacterial cell envelope. The FASII reductase enoyl-ACP reductase (FabI) has been the focus of numerous drug discovery efforts, some of which have led to clinical trials, yet few studies have focused on FabG. Like FabI, FabG appears to be essential for survival in many bacteria, similarly indicating the potential of this enzyme as a drug target. FabG enzymes are members of the short-chain alcohol dehydrogenase/reductase (SDR) family, and like other SDRs, exhibit highly conserved secondary and tertiary structures, and contain a number of conserved sequence motifs. Here we describe the crystal structures of FabG from *Yersinia pestis* (*Yp*FabG), the causative agent of bubonic, pneumonic, and septicemic plague, and three human pan-demics. *Y. pestis* remains endemic in many parts of North America, South America, Southeast Asia, and Africa, and a threat to human health. *Yp*FabG shares a high degree of structural similarity with bacterial homologues, and the ketoreductase domain of the mammalian fatty acid synthase from both *Homo sapiens* and *Sus scrofa*. Structural characterisation of *Yp*FabG, and comparison with other bacterial FabGs and the mammalian fatty acid synthase, provides a strong platform for virtual screening of potential inhibitors, rational drug design, and the development of new antimicrobial agents to combat *Y. pestis* infections.

Introduction

Ketoacyl-acyl carrier protein reductases (FabG; EC 1.1.1.100) are highly conserved and ubiquitously expressed enzymes of the bacterial type II fatty acid synthesis (FASII) pathway, catalysing the reduction of the acyl carrier protein (ACP) linked β-ketoacyl molecules to β-hydroxyacyl-ACP thioesters necessary for the formation of saturated and unsaturated fatty...
acids. Such fatty acids are essential components of the many lipoproteins, phospholipids, and lipopolysaccharides that are incorporated into the bacterial cell envelope [1]. The FASII pathway is structurally distinct from the type I fatty acid synthesis (FASI) pathway of mammals and yeast, with the acyltransferase, condensation, reduction, and dehydration reactions of the pathway catalysed by discrete enzymes, in contrast to the multi-domain complex of the FASI pathway (FAS; also referred to by the gene name FASN) (Fig 1). In Escherichia coli and Yersinia pestis, the elongation of fatty acids typically begins with the condensation of malonyl-ACP and a fatty acyl-thioester catalysed by one of the three β-ketoacyl-ACP synthases (FabB, FabF, or FabH) forming a β-ketoacyl-ACP molecule, which is subsequently reduced by FabG. The product of this reaction is then dehydrated by a β-hydroxyacyl-ACP dehydrase (either FabA or FabZ) to yield enoyl-ACP. Another reductase of the FASII pathway, enoyl-ACP reductase (FabI), reduces enoyl-ACP, forming an acyl-ACP molecule. This acyl-ACP molecule can then re-enter the elongation cycle as a substrate for FabB or FabF, or be diverted to other pathways for the production of lipid molecules [1–3]. The structural differences between the FASI complex and the dissociated enzymes of the FASII pathway indicate the potential of FASII enzymes as antibacterial drug targets. Whilst the FASII enzyme enoyl-ACP reductase (FabI) has been the focus of numerous drug discovery efforts, some of which have led to clinical trials, few studies appear to be focused on FabG [4–9]. Like FabI, FabG appears to be essential for survival in many bacteria, similarly indicating the potential of this enzyme as a drug target [10–13].

FabG enzymes are members of the short-chain alcohol dehydrogenase/reductase (SDR) family (also known as the short chain oxidoreductase or SCOR family) [16]. SDR enzymes are known to catalyse a wide range of NAD(H) or NADP(H) dependent oxidoreduction reactions, and share a conserved nucleotide binding Rossmann fold motif consisting of a twisted β-sheet flanked by α-helices. SDR enzymes typically contain the NAD(P)(H) binding motif T[GxxG] within the Rossmann fold, and catalytic tyrosine and lysine residues in a [YxxK] sequence motif, as well as other fingerprint sequence motifs [17, 18]. The reaction mechanism of classical type SDRs, including FabG, is initiated by the transfer of a proton from the active site tyrosine and a hydride ion donated by the nicotinamide moiety of the co-factor. The active site lysine binds the co-factor and serves to lower the pKa of the tyrosine hydroxyl, facilitating the proton transfer and forming a proton relay with ordered solvent molecules to replenish the tyrosine proton donated during catalysis [19]. A conserved asparagine residue binds the active site lysine via an ordered water molecule, stabilizes the formation of this proton relay, and is essential for catalysis. Historically, a defining feature of the active sites of SDRs was the presence of this Ser-Tyr-Lys catalytic triad. It has been proposed that this active site triad be expanded to include the conserved asparagine residue, however others have argued the asparagine residue is not directly involved in catalysis and thus not part of a catalytic tetrad, leading to a discrepancy in the literature regarding the catalytic residues of SDR and FabG enzymes [19–21].

Here we describe the crystal structure of FabG from Yersinia pestis (YpFabG). The causative agent of bubonic, pneumonic, and septicaemic plague, and three human pandemics, Y. pestis remains endemic in many parts of North America, South America, Southeast Asia, and Africa [22–25], and a threat to human health. Structural characterisation of YpFabG may provide a platform for rational drug design and the development of new antimicrobial agents to combat Y. pestis infections.

Materials and Methods
Cloning, expression, and purification
The gene encoding Y. pestis FabG (GenBank accession number: AAM85326.1), a low molecular weight FabG of 244 amino acids, was cloned into the expression vector pMCSG21, solubly
over-expressed, and purified as previously described [26]. Briefly, the gene encoding YpFabG was amplified from genomic DNA and cloned into the expression vector pMCSG21 via ligation independent cloning. Plasmid containing recombinant YpFabG was transformed into E. coli BL21(DE3) pLysS cells and expressed in auto-induction media [27] as a fusion protein containing a 6xHis tag and a Tobacco etch virus (TEV) protease cleavage site for tag removal. Cells were harvested by centrifugation, lysed by ~0.5 mg mL⁻¹ lysozyme and two freeze/thaw cycles, and the cell lysate clarified by centrifugation. Soluble YpFabG was purified by 6xHis affinity chromatography, and fractions containing YpFabG were pooled, incubated with TEV protease for ~14 h at 4°C, and further purified by size-exclusion chromatography. Following size-exclusion chromatography, fractions containing YpFabG were pooled, concentrated, and stored at -80°C.

**Crystallisation**

Crystal screening was performed using the hanging-drop vapour-diffusion technique and commercial screens. Initial diffraction-quality crystals were obtained in 300mM ammonium phosphate monobasic, 30% (w/v) glycerol, using a protein concentration of 35mg ml⁻¹ as previously
The electron density maps generated from the previously reported crystallization data indicated a high degree of disorder in half of the asymmetric unit (ASU). As such, crystallisation conditions were further optimised using an additive screen (Hampton Research), with droplets consisting of 1.5 μL of protein solution, and 1.5 μL of a 1:1 mix of additive and reservoir solutions, mixed and suspended over 300 μL of reservoir solution (300 mM ammonium phosphate monobasic). After one week, two conditions formed crystals of sufficient quality for data collection; one obtained with 300 mM ammonium phosphate monobasic and 30% (w/v) trimethylamine N-oxide dihydrate (TMAO) solution, and the other with 300 mM ammonium phosphate monobasic and 100 mM sodium bromide (NaBr).

Data collection, structure determination, refinement, and analysis
Prior to data collection, all YpFabG crystals were cryoprotected in 35% glycerol and flash-cooled in liquid nitrogen. Diffraction data were collected on the MX1 beamline at the Australian synchrotron. A total of 200° of data with 0.5° oscillations were collected at a wavelength of 0.7108 Å for both crystals. Diffraction data were indexed, integrated, and scaled using iMosflm [28] and Aimless [29] from the CCP4 suite [30, 31]. Diffraction data for the crystal obtained in the presence of TMAO were scaled to 2.50 Å, and diffraction data for the crystal obtained in the presence of NaBr were scaled to 2.85 Å. The YpFabG crystals displayed different space groups, with the TMAO crystal displaying P42212 symmetry, with the unit cell lengths \( a = 88.21, \ b = 88.21, \ c = 54.21 \) Å, and the NaBr crystal displaying P1211 symmetry, with the unit cell parameters \( a = 64.74, \ b = 96.85, \ c = 71.55 \) Å, \( \alpha = 90, \ \beta = 104.91, \ \gamma = 90^\circ \). The structures were solved by molecular replacement performed with Phaser [32], using a monomer of YpFabG built from previously acquired data [26] as the search model. Further model building and refinement was performed using Coot [33] and PHENIX [34]. Structural renderings were performed in PyMol. The quaternary structure of YpFabG and protein interfaces were investigated using the Protein Interfaces, Surfaces, and Assemblies’ service (PISA) from the European Bioinformatics Institute (http://www.ebi.ac.uk/pdbe/prot_int/pistart.html) [35]. Sequence alignments were generated using the T-Coffee (http://tcoffee.crg.cat/) [36, 37] and ESPript (http://escript.ibcp.fr/) [38] web services. Structural alignments were performed using the Protein structure comparison service (PDBeFold) at the European Bioinformatics Institute (http://www.ebi.ac.uk/msd-srv/ssm) [39, 40]. A summary of the crystallographic and refinement statistics for YpFabG structures are provided in Table 1.

Enzyme assays
The reductase activity of YpFabG was measured by the decrease of absorbance at 340 nm as a function of NADH or NADPH oxidation using a molar extinction coefficient of 6220 M\(^{-1}\) cm\(^{-1}\), similarly to that described previously [7, 9, 13, 41, 42]. Reaction mixtures contained co-factor, acetoacetyl-CoA, and 0.10 μg of recombinant YpFabG, made to a final volume of 100 μL in a 96 well UV-transmissible plate with a solution of 125 mM NaCl and 25 mM HEPES pH 7.4, with the reaction initiated by the addition of substrate. NADH/NADPH oxidation without the addition of acetoacetyl-CoA served as a blank. Each assay was performed in at least triplicate. The decrease in absorbance at 340 nm was recorded over 4 min, and readings for the linear portion of the assay (typically over 45 s) were used in analyses. Co-factor specificity was determined using 200 μM co-factor and 500 μM acetoacetyl-CoA. \( K_m \) and \( V_{max} \) were determined by varying the concentration of either NADPH or acetoacetyl-CoA, while maintaining a fixed concentration of the other. \( K_m \) and \( V_{max} \) were calculated via nonlinear regression analyses with GraphPad Prism.
Overall structure of YpFabG

To determine the high resolution crystal structure of FabG from *Y. pestis* (YpFabG), a potentially important drug target, recombinant YpFabG was expressed and purified from *E. coli*, and crystallised by hanging drop vapour diffusion. Recombinant YpFabG crystallised in two different crystal forms; YpFabG crystallised in the presence of TMAO (YpFabG TMAO) diffracted to 2.5 Å and contained one monomer in the ASU, with electron density visible for 234 of 244 residues (residues 2–189, and 197–241), and was refined to Rwork/Rfree values of 0.220/0.255. YpFabG crystallised in the presence of NaBr (YpFabG NaBr) diffracted to 2.85 Å and contained a homotetramer in the ASU, with electron density visible for 832 of 976 residues, with disordered regions between residues 139–147 and 185–206 in each monomer, and was refined to Rwork/Rfree values of 0.214/0.248. Overall, the structures were similar, with an RMSD of 0.35 Å over 205 amino acids, however they also contained some important structural differences.

The refined structures of the two crystal forms of YpFabG reveal that the protein contains a typical Rossmann fold motif, comprised of a seven strand twisted β-sheet surrounded by eight α-helices. YpFabG can be divided into three motifs, two βαβαβ motifs and a single αααβ motif (Fig 2). The first βαβαβ motif is comprised of β-strands β1, β2, and β3, and α-helices α1 and α2, and is connected to the second βαβαβ motif, containing β-strands β4, β5, and β6, and α-helices α4 and α5, by helix α3. The final motif contains a helix-turn-helix feature formed by α6 and α7 that lies away from the central β-sheet of the Rossmann fold, and helix α8 and strand...
β7, which align adjacent to strand β6. Overall, these secondary structure elements are arranged in a topology of β1-α1-β2-α2-β3-α3-β4-α4-β5-α5-β6-α6-β7-α7-α8-β8 (Fig 2). These secondary structure elements are clearly observable in the YpFabG TMAO structure, with only residues 190–197, which form part of the helix-turn-helix motif comprised of helices α6 and α7, and the loop region connecting the two helices, unmodelled due to disorder. Conversely, this helix-turn-helix motif is completely disordered in our YpFabG NaBr structure.

Despite similar crystallisation conditions, several differences were observed between the structures of YpFabG TMAO and YpFabG NaBr, including large differences surrounding the co-factor binding pocket. The conformation of the helix-turn-helix motif found in the YpFabG TMAO structure closely resembles that of E. coli FabG bound to NADP+ (PDB entry 1q7b; [19]), despite the apparent absence of bound co-factor in our structure. In contrast, a greater portion of the helix-turn-helix motif is disordered in the YpFabG NaBr structure, with little visible electron density in this region (Fig 3). The ordered residues of this motif appear to adopt a conformation similar to that of unbound E. coli FabG (PDB entry 1i01; [16]), with superposition of both the NADP+ bound and unbound E. coli structures onto the YpFabG structures revealing the helix-turn-helix motif of YpFabG NaBr is incompatible with NADPH binding, indicating this region is highly flexible. Furthermore, the loop joining β-strand β5 and α-helix α5 within the YpFabG NaBr structure is largely disordered, with superposition of NADP+ bound and unbound E. coli FabG structures indicating that Ser138 located at the start of this

**Fig 2. The tertiary structure of Yersinia pestis FabG (YpFabG).** (A) A cartoon representation of YpFabG TMAO showing the central seven strand twisted β-sheet flanked either side by α-helices. (B) A 2D depiction of the secondary structure features of YpFabG, with the two ββαβαβαβ and αααβαβαβ motifs highlighted by grey squares. (C) The amino acid sequence of YpFabG, and corresponding secondary structure features. β-sheets are displayed yellow; α-helices are displayed red; loop regions are displayed green.

doi:10.1371/journal.pone.0141543.g002
loop region must move ~3 Å to accommodate the nicotinamide portion of NADP+. In comparison, this region is ordered within the YpFabG TMAO structure, and adopts a conformation almost identical to that of E. coli FabG in complex with NADP⁺ [19]. The cause of this conformational change is not apparent. The conformation that appears to mimic that of E. coli FabG in complex with NADP⁺ could possibly be induced by crystal contacts, or the presence of TMAO within a binding pocket that becomes occupied by the 2’-phosphate of NADPH upon co-factor binding [19]. A similar conformation was observed in the crystal structure of Plasmodium falciparum FabG [7], where a sulphate ion bound within the same phosphate binding pocket of the NADPH binding site appeared to induce a conformation mimicking that of the NADPH bound active conformation previously observed in E. coli FabG [7, 19]. A single phosphate molecule is observed within the same location in our YpFabG NaBr structure, however the presence of this molecule in only one monomer may not be sufficient to induce this active conformation.

The conformational changes and flexibility observed in the NADP(H) binding site of YpFabG and E. coli FabG may pose an issue for structure-based drug design or virtual screening of potential antimicrobial agents, thus such studies should consider that inhibitors which demonstrate competitive binding in regards to NADPH, or mimic NADPH, may be incompatible without first taking into account conformation changes within this binding site.

Co-factor specificity of YpFabG

The structures of YpFabG, particularly the presence of a charged pocket for the 2’-phosphate of NADPH, indicated the catalytic mechanism of YpFabG to be NADP dependent. To confirm this, the ketoacyl reductase activity of YpFabG was assessed by the oxidation of NADH or NADPH in the presence of acetoacetyl-CoA, similarly to that described previously [7, 9, 13, 41, 42].
The enzymatic activity assays confirmed YpFabG reductase activity is highly dependent upon NADPH as the co-factor, with little reductase activity occurring in the presence of NADH (Fig 4). YpFabG was found to catalyse the reduction of acetoacetyl-CoA with a $K_m$ of $329.9 \pm 31.2 \mu M$ in the presence of $0.9 \text{mM NADPH}$. The $K_m$ for NADPH was $55.1 \pm 3.8 \mu M$ in the presence of $1.5 \text{mM acetoacetyl-CoA}$. $V_{max}$ with respect to acetoacetyl-CoA was $0.383 \pm 0.010 \mu$moles min$^{-1}$ μg$^{-1}$.

Quaternary structure of YpFabG

Despite very similar crystallisation conditions, the YpFabG TMAO crystal displays $P4_212_1$ symmetry with a single YpFabG monomer within the ASU, whereas the YpFabG NaBr crystal displays $P12_11$ symmetry with four YpFabG monomers within the ASU arranged to form a homotetramer. Crystallographic symmetry of YpFabG TMAO arrange to form a tetramer highly similar to that within the ASU of YpFabG NaBr, with superposition of the YpFabG NaBr structure and the tetramer of YpFabG TMAO generated through crystallographic symmetry indicating no clashes that would alter crystal packing. The only obvious difference between the two tetraters is the presence of the loop joining β-strand β5 and α-helix α5 (residues 139–147), and the helix-turn-helix motif (residues 185–205) in the YpFabG TMAO structure, which are largely disordered in the YpFabG NaBr structure (Fig 3). These regions appear to alter crystal packing, with symmetry generated YpFabG TMAO tetraters packing in parallel, and the helix-turn-helix motifs of each monomer packing against the same motif of the symmetry mate, whilst symmetry mates of the YpFabG NaBr structure appear to form crystal contacts primarily through helices α1, α2, and α3 at the corner of each tetramer.

Analysis of the quaternary structure of YpFabG TMAO using PISA predicts the biological unit of YpFabG to be a tetramer, with symmetry similar to that observed in the YpFabG NaBr ASU. The YpFabG tetramer is formed through two types of interfaces (Fig 5). The largest interface in terms of buried surface area is between chains A and D, and B and C (A/D interface), comprising $1,653 \AA^2$ (~15%) of the total surface area with an estimated binding energy of -119 kJ mol$^{-1}$, formed through interactions between helices α4 and α5 of each monomer, which align antiparallel to form a four helix bundle (Fig 5). Whilst the interface between helices α4 and α5 and counterparts on the opposing monomer appear to be formed primarily through hydrophobic packing, PISA analysis suggests the interface is also stabilised by several hydrogen bonds and four salt bridges (Table 2). The smaller of the two interfaces exists between chains A and B, and C and D (A/B interface), comprising $1360 \AA^2$ (~12%) of the total surface area, with an estimated binding energy of -97 kJ mol$^{-1}$. In contrast to the larger interface between helices α4 and α5 of each monomer, this interface appears to be predominantly formed by hydrogen bonds and salt bridges (Table 2). These interactions are mostly between helix α8, strand β7, and the adjoining loop region of each monomer, which align in an antiparallel fashion, with the β7 strand of each monomer arranged to form a contiguous 14 strand β-sheet that spans the dimer interface (Fig 5).

Comparison of YpFabG with the ketoreductase domain of mammalian FAS and SDRs

A structural homology search of the PDB database using PDBeFold shows the most similar enzymes to YpFabG are FabG enzymes from E. coli (PBD entry 1q7b; [19]), Vibrio cholera (PBD entry 3rsh; unpublished), Pseudomonas aeruginosa (PBD entry 3rsh; [8]) and Neisseria meningitidis (PBD entry 4m8s; unpublished), with RMSD values of 0.59 Å over 234 residues, 0.67 Å over 229 residues, 0.85 Å over 210 residues, and 1.01 Å over 228 residues, respectively. YpFabG also shares a high degree of structural homology with the ketoreductase (KR) domain.
of the mammalian FAS enzymes from both *Sus scrofa* (PDB entry 2vz8; [43]) and *Homo sapiens* (PDB entry 4PIV; [44]) (Fig 6), with RMSD values of 2.24 Å over 208 amino acids and 2.10 Å over 205 amino acids, respectively, and with 3α, 20β-hydroxysteroid dehydrogenase (PDB entry 2hsd; [45]), the first member of the SDR family for which the crystal structure was reported, with an RMSD of 1.34 Å over 230 amino acids, despite sequence identities of 18%, 19% and 26% respectively. Furthermore, FabG exhibits little deviation from the 40 highly conserved fingerprint motifs observed in 3α, 20β-hydroxysteroid dehydrogenase, and characteristic of TGxxxxGIG SDRs [17, 18]. Only 1 out of 40 residues (Asn59Asp) deviates from the highly conserved fingerprint residues, with this alteration also present in *E. coli, V. cholerae*, and *N. meningitidis* FabG homologues.

Fig 4. The co-factor specificity and enzymatic activity of *Yersinia pestis* FabG (YpFabG). (A) The activity of YpFabG in the presence of NADH (●) or NADPH (○) confirmed YpFabG reductase activity is highly dependent upon NADPH as the co-factor. YpFabG was assayed in the presence of acetoacetyl-CoA and NADPH, by varying the concentration of either acetoacetyl-CoA (B) or NADPH (C) while maintaining a fixed concentration of the other. The $K_m$ values of acetoacetyl-CoA and NADPH were 329.9 ± 31.2 μM and 55.1 ± 3.8 μM respectively.

doi:10.1371/journal.pone.0141543.g004
Despite this highly conserved tertiary structure, there are significant structural differences between FabG enzymes and the KR domain of the mammalian FAS surrounding the co-factor binding site (Fig 6), including a rearrangement of the active site lysine and the structurally conserved asparagine required for catalysis in the mammalian FAS, and configuration of the electropositive arginine residues surrounding the 3’ phosphate of NADP(H). The helix turn helix motif that caps the co-factor binding site also appears shorter in both the human and \textit{S. scrofa} mammalian FAS compared to bacterial FabG enzymes (Fig 6), however this could be due to the inherent flexibility of this region. Comparison between bacterial FabG enzymes and the structure of the human FAS KR domain bound by the inhibitor GSK2194069 (PDB entry 4PIV; [44]) highlights important differences within the quaternary structure of the mammalian FAS and that of bacterial FabG enzymes. GSK2194069 binds the KR domain of human FAS along a groove that extends from the KR domain active site, adjacent to the nicotinamide portion of the co-factor, into the interface between the KR domain and the pseudo-methyltransferase domain of the FAS complex [44]. Within the \textit{YpFabG} and \textit{E. coli} FabG structures, this groove extends towards the A/B dimer interface and the center of the tetramer, with superposition of the KR domain in complex with GSK2194069, \textit{YpFabG}, and \textit{E. coli} FabG structures indicating GSK2194069 is incompatible with these bacterial FabG enzymes, clashing with residues Met143, Phe183, Met241, and Tyr242, which protrude into this groove (Fig 7A).

Such differences may be exploited during the design of new antimicrobials targeting the bacterial FabG enzymes, potentially reducing their affinity for the mammalian FAS complex and

---

**Fig 5.** The quaternary structure of \textit{Yersinia pestis} FabG (\textit{YpFabG}). (A) A cartoon representation of the \textit{YpFabG} TMAO homo-tetramer, the biological unit as indicated by PISA. (B) \textit{YpFabG} forms a tetramer with two types of interfaces. The larger of the two interfaces in terms of buried surface area (A/D interface) is formed primarily through interactions between helices \(\alpha4\) and \(\alpha5\) of each monomer, which align antiparallel to form a four helix bundle. (C) The smaller of the two interfaces (A/B interface) is formed through interactions between helix \(\alpha8\), strand \(\beta7\), and the adjoining loop region of each monomer, which align antiparallel, with the \(\beta7\) strand of each monomer arranged to form a contiguous 14 strand \(\beta\)-sheet that spans the dimer interface. Opposing monomer secondary structure features are indicated by asterisks (*).
Table 2. Hydrogen bonds and salt bridges of the YpFabG dimer interfaces.

| Hydrogen bonds | Interactions within the A/D interface | Salt bridges |
|----------------|--------------------------------------|--------------|
| Chain A Dist. [Å] | Chain D | Chain A Dist. [Å] | Chain D |
| LYS 119 [NZ] | 3.61 | LEU 95 [O] | ARG 116 [NH2] | 3.14 | ASP 100 [OD2] |
| LYS 119 [NZ] | 2.73 | MET 98 [O] | ARG 116 [NE] | 3.09 | ASP 100 [OD2] |
| ARG 116 [NH2] | 3.14 | ASP 100 [OD2] | ASP 100 [OD2] | 3.09 | ARG 116 [NE] |
| ARG 116 [NE] | 3.09 | ASP 100 [OD2] | ASP 100 [OD2] | 3.14 | ARG 116 [NH2] |
| TRP 103 [NE1] | 3.11 | THR 112 [OG1] | |
| LYS 163 [NZ] | 2.51 | THR 142 [O] | |
| ARG 167 [NH2] | 2.80 | MET 143 [O] | |
| SER 164 [OG] | 2.21 | ASN 145 [O] | |
| ASN 145 [N] | 3.90 | SER 164 [OG] | |
| GLY 147 [N] | 2.96 | GLU 168 [OE1] | |
| LEU 95 [N] | 2.50 | GLU 168 [OE2] | |
| LEU 95 [O] | 3.61 | LYS 119 [NZ] | |
| MET 98 [O] | 2.73 | LYS 119 [NZ] | |
| ASP 100 [OD2] | 3.09 | ARG 116 [NE] | |
| ASP 100 [OD2] | 3.14 | ARG 116 [NH2] | |
| THR 112 [OG1] | 3.11 | TRP 103 [NE1] | |
| THR 142 [O] | 2.51 | LYS 163 [NZ] | |
| MET 143 [O] | 2.80 | ARG 167 [NH2] | |
| ASN 145 [O] | 2.21 | SER 164 [OG] | |
| SER 164 [OG] | 3.90 | ASN 145 [N] | |
| GLU 168 [OE1] | 2.96 | GLY 147 [N] | |
| GLU 168 [OE2] | 2.50 | LEU 95 [N] | |

| Interactions within the A/B interface | Salt bridges |
|--------------------------------------|--------------|
| Chain A Dist. [Å] | Chain B | Chain A Dist. [Å] | Chain B |
| SER 171 [N] | 3.67 | PRO 205 [O] | ARG 28 [NH2] | 3.41 | GLU 226 [OE1] |
| TYR 229 [OH] | 2.99 | ARG 208 [O] | ARG 28 [NH1] | 3.61 | GLU 226 [OE2] |
| TYR 229 [N] | 3.78 | GLU 214 [OE1] | ARG 28 [NH2] | 2.80 | GLU 226 [OE2] |
| ARG 28 [NH2] | 2.80 | GLU 226 [OE2] | ARG 167 [NH1] | 3.72 | TYR 242 [O] |
| SER 217 [OG] | 3.17 | GLU 226 [OE2] | ARG 167 [NH2] | 2.52 | TYR 242 [O] |
| ARG 208 [NH2] | 3.50 | SER 228 [OG] | GLU 226 [OE1] | 3.41 | ARG 28 [NH2] |
| ASN 238 [N] | 3.28 | TYR 229 [O] | GLU 226 [OE2] | 3.61 | ARG 28 [NH1] |
| GLY 239 [N] | 2.62 | TYR 229 [O] | GLU 226 [OE2] | 2.80 | ARG 28 [NH2] |
| HIS 236 [N] | 2.86 | GLU 233 [OE2] | TYR 242 [O] | 3.72 | ARG 167 [NH1] |
| ARG 167 [NH2] | 2.52 | TYR 242 [O] | TYR 242 [O] | 2.52 | ARG 167 [NH2] |
| PRO 205 [O] | 3.67 | SER 171 [N] | |
| ARG 208 [O] | 2.99 | TYR 229 [OH] | |
| GLU 214 [OE1] | 3.78 | TYR 229 [N] | |
| GLU 226 [OE2] | 2.80 | ARG 28 [NH2] | |
| GLU 226 [OE2] | 3.17 | SER 217 [OG] | |
| SER 228 [OG] | 3.50 | ARG 208 [NH2] | |
| TYR 229 [O] | 3.28 | ASN 238 [N] | |
| TYR 229 [O] | 2.62 | GLY 239 [N] | |
| GLU 233 [OE2] | 2.86 | HIS 236 [N] | |
| TYR 242 [O] | 2.52 | ARG 167 [NH2] | |

doi:10.1371/journal.pone.0141543.t002
thus limiting adverse host effects. For example, inhibitors that rely upon interactions with Met143, Phe183, Met241, and Tyr242, or other residues of the FabG dimer interfaces, may exhibit little affinity for the mammalian FAS KR domain.

Reported inhibitors and potential lead compounds

Whilst current FabG inhibitors do not appear to have progressed to the stage of clinical trials, a number of lead molecules and inhibitors have been reported [4–8]. The most potent of these molecules in terms of inhibitory activity are a class of allosteric inhibitors reported by Cukier et al. (2013), with IC_{50} values ranging from 138 μM to 20 nM [8], that bind within the A/D and B/C dimer interfaces of FabG between helices α4 and α5 of each monomer (Fig 4B), and appear...
to distort the NADPH binding pocket sufficiently to inhibit binding of the co-factor. Whilst the allosteric inhibitors reported by Cukier et al. (2013) target the dimer interfaces of FabG and might be highly selective for bacterial FabG enzymes, neither the activity of these inhibitors against the mammalian FAS, or minimum inhibitory concentration (MIC) values against bacteria have been reported [8]. Furthermore, while the KR domain of the mammalian FAS complex does not possess the same interfaces as bacterial FabG enzymes, the mammalian FAS does contain a region somewhat homologous to the A/D interface. However, two of the four helices of this site are truncated in comparison to FabG, thus such structural differences may be able to be exploited to reduce the affinity of the inhibitor for the mammalian FAS. Opposing monomer secondary structure features are indicated by asterisks (*).

doi:10.1371/journal.pone.0141543.g007

Similarly, Macrolactin B and Macrolactin S have been reported to inhibit *Staphylococcus aureus* FabG, with IC$_{50}$ values of 100 μM and 130 μM respectively, and exhibit weak antibacterial activity against *E. coli*, *Bacillus subtilis* and *S. aureus*, with MIC$_{50}$ values ranging from 64 to 128 μg mL$^{-1}$. However, any structural data pertaining to the mechanism of inhibition of these Macrolactins, or the activity of these molecules against the mammalian FAS KR domain, if any, is yet to be reported [4].

The triclosan (a widely used FabI inhibitor) analogues hexachlorophene, bithionol, di-resorcinol sulphide, and bromochlorophene have all been shown to inhibit *P. falciparum* FabG, with...
IC$_{50}$ values for these compounds ranging from 2.05 μM for hexachlorophene to 15.4 μM for bromochlorophene [7]. While no structural data detailing the binding of these molecules has been reported, hexachlorophene has been shown to inhibit *P. falciparum* FabG in a competitive mechanism in regards to NADPH, and a mixed inhibition mechanism in regards to the fatty acyl substrate [7]. Due to the highly similar structure of these molecules, it would seem likely that they would share a common mechanism of inhibition, and virtual screening or docking studies may provide an avenue for further investigation of these inhibitors or related molecules. A combination of molecular docking and *in vitro* analysis led to the discovery of another triclosan analogue (OAR27), able to inhibit *Schistosoma japonicum* FabG with an IC$_{50}$ value of 51 μM. The compound (OAR27) displayed cytotoxicity in human liver carcinoma cells [6], indicating OAR27 may possess some activity against the KR domain of human FAS, yet this could possibly be reduced with optimisation using the structures of *Yp*FabG and other bacterial FabG enzymes as a basis for such drug design.

With the exception of the allosteric inhibitors reported by Cukier et al. (2013) [8], no structural data indicating the amino acids or functional groups required for the interactions between FabG and these inhibitors have been reported, thus the three-dimensional structure of FabG bound to these inhibitors, or rigorous virtual screening followed by site-directed mutagenesis to confirm any apparent interactions, would be necessary to allow a structure-based drug design approach. Once the binding site of these inhibitors and residues required for protein/inhibitor interaction are known, these compounds could be further altered to enhance the affinity for *Yp*FabG and bacterial FabGs, and reduce the affinity for the KR domain of mammalian FAS.

**Conclusion**

Here we describe x-ray structures of FabG from *Yersinia pestis*. FabG is a highly conserved and ubiquitously expressed ketoacyl-ACP reductase of the bacterial FASII pathway, and a key component of bacterial lipogenesis. *Yp*FabG crystallised in two different crystal forms, one differing to 2.50 Å, and the other to 2.85 Å. The two crystal forms were highly similar, with an RMSD of 0.35 Å over 205 amino acids, yet displayed differences within two loop regions adjacent to the NADP(H) binding site. The structures of *Yp*FabG exhibit high structural homology with other SDRs (RMSD of 0.59–2.24 Å), including the ketoreductase domain of the mammalian FAS from *Homo sapiens* and *Sus scrofa*, despite sequence homologies from as little as 18%. However, further comparison of *Yp*FabG to the human and *S. scrofa* FAS enzymes also reveals structural differences surrounding the NADP(H) binding site and dimer interfaces, with the potential for such differences to be exploited during structure-based drug design of new antimicrobial agents to combat *Y. pestis* infections that exhibit poor affinity for mammalian homologues, thus limiting adverse host effects.

**Acknowledgments**

We thank the beamline scientists and staff of the Australian Synchrotron for their assistance. We thank Gayle Petersen for proofreading of the manuscript. JKF is an ARC (Australian Research Council) Future Fellow.

**Author Contributions**

Conceived and designed the experiments: JDN JKF. Performed the experiments: JDN. Analyzed the data: JDN JKF. Contributed reagents/materials/analysis tools: JDN JKF. Wrote the paper: JDN JKF.
References

1. Parsons JB, Rock CO. Bacterial lipids: metabolism and membrane homeostasis. Progress in lipid research. 2013; 52(3):249–76. doi: 10.1016/j.plipres.2013.02.002 PMID: 23500459

2. Janssen HJ, Steinbuchel A. Fatty acid synthesis in Escherichia coli and its applications towards the production of fatty acid based biofuels. Biotechnology for biofuels. 2014; 7(1):7. doi: 10.1186/1754-6834-7-7 PMID: 24405789

3. Zhang YM, Rock CO. Membrane lipid homeostasis in bacteria. Nature reviews Microbiology. 2008; 6(3):222–33. doi: 10.1038/nrmicro1839 PMID: 18264115

4. Sohn MJ, Zheng CJ, Kim WG. Macrolactin S, a new antibacterial agent with FabG-inhibitory activity from Bacillus sp. AT28. J Antibiot (Tokyo). 2008; 61(11):687–91.

5. Banerjee DR, Dutta D, Saha B, Bhattacharyya S, Senapati K, Das AK, et al. Design, synthesis and characterization of novel inhibitors against mycobacterial beta-ketoacyl CoA reductase FabG4. Org Biomol Chem. 2014; 12(1):73–85. doi: 10.1039/c3ob41767c PMID: 24129589

6. Liu J, Dyer D, Wang J, Wang S, Du X, Xu B, et al. 3-oxoacyl-ACP reductase from Schistosoma japonicum: integrated in silico-in vitro strategy for discovering antischistosomal lead compounds. PLoS One. 2013; 8(6):e64984. doi: 10.1371/journal.pone.0064984 PMID: 23762275

7. Wickramasinghe SR, Inglis KA, Urch JE, Muller S, van Aalten DM, Fairlamb AH. Kinetic, inhibition and structural studies on 3-oxoacyl-ACP reductase from Plasmodium falciparum, a key enzyme in fatty acid biosynthesis. Biochem J. 2006; 393(Pt 2):447–57. PMID: 16225460

8. Cukier CD, Hope AG, Elamin AA, Moynie L, Schnell R, Schach S, et al. Discovery of an allosteric inhibitor binding site in 3-Oxo-acyl-ACP reductase from Pseudomonas aeruginosa. ACS chemical biology. 2013; 8(11):2518–27. doi: 10.1021/cb4005063 PMID: 24015914

9. Dutta D, Bhattacharyya S, Roychowdhury A, Biswas R, Das AK. Crystal structure of hexanoyl-CoA bound to beta-ketoacyl reductase FabG4 of Mycobacterium tuberculosis. Biochem J. 2013; 450(1):127–39. doi: 10.1042/BJ20121107 PMID: 23163771

10. Shen Y, Liu J, Estiu G, Isin B, Ahn YY, Lee DS, et al. Blueprint for antimicrobial hit discovery targeting metabolic networks. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107(3):1082–7. doi: 10.1073/pnas.0909181107 PMID: 20085087

11. Martinez MA, de Mendoza D, Schujman GE. Transcriptional and functional characterization of the gene encoding acyl carrier protein in Bacillus subtilis. Microbiology. 2010; 156(Pt 2):484–56. PMID: 205. doi:10.1093/nar/gkt1076 PMID: 24214961

12. Zhang Y, Cronan JE Jr. Transcriptional analysis of essential genes of the Escherichia coli fatty acid biosynthesis gene cluster by functional replacement with the analogous Salmonella typhimurium gene cluster. Journal of bacteriology. 1998; 180(13):3295–303. PMID: 9642179

13. Lai CY, Cronan JE. Isolation and characterization of beta-ketoacyl-acyl carrier protein reductase (fabG) mutants of Escherichia coli and Salmonella enterica serovar Typhimurium. Journal of bacteriology. 2004; 186(6):1869–78. PMID: 14996618

14. Kanehisa M, Goto S, Sato Y, Kawashima M, Furumichi M, Tanabe M, et al. The KEGG database in 2004. Nucleic acids research. 2004; 32(Database issue):D277–82. doi: 10.1093/nar/gkh037 PMID: 14780163

15. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic acids research. 2000; 28(1):27–30. PMID: 10592173

16. Price AC, Zhang YM, Rock CO, White SW. Structure of beta-ketoacyl-[acyl carrier protein] reductase from Escherichia coli: negative cooperativity and its structural basis. Biochemistry. 2001; 40(43):12772–81. PMID: 11669613

17. Kallberg Y, Oppermann U, Jornvall H, Persson B. Short-chain dehydrogenases/reductases (SDRs). European journal of biochemistry / FEBS. 2002; 269(18):4409–17. PMID: 12230552

18. Duax WL, Thomas J, Pletnev V, Addiagatta A, Huether R, Habegger L, et al. Determining structure and function of steroid dehydrogenase enzymes by sequence analysis, homology modeling, and rational mutational analysis. Annals of the New York Academy of Sciences. 2005; 1061:135–48. PMID: 16467263

19. Price AC, Zhang YM, Rock CO, White SW. Cofactor-induced conformational rearrangements establish a catalytically competent active site and a proton relay conduit in FabG. Structure. 2004; 12(3):417–28. PMID: 15016358

20. Oppermann U, Filling C, Hult M, Shafqat N, Wu X, Lindh M, et al. Short-chain dehydrogenases/reductases (SDRs): the 2002 update. Chemico-biological interactions. 2003; 143–144:247–53.

21. Filling C, Berndt KD, Benach J, Knapp S, Prozorovski T, Nordling E, et al. Critical residues for structure and catalysis in short-chain dehydrogenases/reductases. The Journal of biological chemistry. 2002; 277(28):25677–84. PMID: 11976334
44. Hardwicke MA, Rendina AR, Williams SP, Moore ML, Wang L, Krueger JA, et al. A human fatty acid synthase inhibitor binds beta-ketoacyl reductase in the keto-substrate site. Nat Chem Biol. 2014; 10 (9):774–9. doi: 10.1038/nchembio.1603 PMID: 25086508

45. Ghosh D, Wawrzak Z, Weeks CM, Duax WL, Erman M. The refined three-dimensional structure of 3 alpha,20 beta-hydroxysteroid dehydrogenase and possible roles of the residues conserved in short-chain dehydrogenases. Structure. 1994; 2(7):629–40. PMID: 7922040